Individual tests

The hepatitis B virus (HBV) is one of the major causes of liver inflammation. The hepatitis B e antigen (HBeAg) appears after an HBV infection. Usually, HBeAg indicates much higher rates of viral replication and enhanced infectivity. However, variants of the hepatitis B virus do not produce the 'e' antigen, so this rule does not always hold. The HBeAg may be cleared, and antibodies to the 'e' antigen (anti-HBe) will arise immediately afterward, suggesting a dramatic decline in viral replication.
This is a viral protein made by the hepatitis B virus that is released from infected liver cells into the blood. A positive HBeAg indicates high virus levels in the blood, with the person considered infectious. A negative result indicates very low to no virus in the blood, and the person is considered less infectious; sometimes, this can indicate a person has a mutant hepatitis B virus.
Hepatitis B is a liver inflammation caused by the type B virus and is one of the most common causes of cirrhosis in Viet Nam. HBsAb is a protein your immune system produces to fight against the hepatitis B virus. The presence of anti-HBs is generally interpreted as indicating recovery and immunity from hepatitis B virus infection. Anti-HBs also develop in a person successfully vaccinated against hepatitis B.
Hepatitis B is a liver inflammation caused by the type B virus and is one of the most common causes of cirrhosis in Viet Nam. Hepatitis B surface antigen (HBsAg) is a protein that appears in the blood when you have a hepatitis B infection.
Hepatitis B is a liver inflammation caused by the type B virus and is one of the most common causes of cirrhosis in Viet Nam. Hepatitis B surface antigen (HBsAg) is a protein that appears in the blood when you have a hepatitis B infection.
HBV-DNA or hepatitis B virus DNA is a measure of the viral load of the hepatitis B virus in the blood. A high HBV-DNA level indicates that the virus is multiplying in the individual’s body and the person is contagious. The test is most often used to monitor the efficacy of antiviral therapy in individuals with chronic HBV infection.
HBV-DNA or hepatitis B virus DNA is a measure of the viral load of the hepatitis B virus in the blood. A high HBV-DNA level indicates that the virus is multiplying in the individual’s body and the person is contagious. The test is most often used to monitor the efficacy of antiviral therapy in individuals with chronic HBV infection.
Hepatitis C is usually spread by contact with blood from an infected person. Most people who get hepatitis C will have a chronic infection. In most cases, medicine can cure hepatitis C. Without treatment, chronic hepatitis C may lead to cirrhosis or liver cancer. This test is used to screen for hepatitis C virus (HCV) infection by detecting HCV antibodies. If the result is positive, the patient must take an HCV ARN test next.
The hepatitis C virus (HCV) is a major cause of liver inflammation. The quantitative HCV RNA PCR test indicates the number of viral copies of HCV in your blood. This test helps establish a diagnosis and monitors the amount of HCV in the bloodstream during treatment. It's also used to assess how well the body is responding to treatment and if any changes are necessary.
The hepatitis C virus (HCV) is a major cause of liver inflammation. The quantitative HCV RNA PCR test indicates the number of viral copies of HCV in your blood. This test helps establish a diagnosis and monitors the amount of HCV in the bloodstream during treatment. It's also used to assess how well the body is responding to treatment and if any changes are necessary.
The hepatitis E virus (HEV) is one of the major etiologic agents of hepatitis worldwide. HEV-antibodies are proteins your immune system produces to fight against HEV following infection. The titer of IgM anti-HEV declines rapidly during early convalescence. IgG anti-HEV persists for a longer timeframe.
The Hepatitis E virus (HEV) is one of the major etiologic agents of hepatitis worldwide. HEV-antibodies are proteins your immune system produces to fight against HEV following infection. The amount of IgM anti-HEV declines rapidly during early convalescence; IgG anti-HEV persists for a long time.
loading.svg